Medicine for preventing and treating heart failure after myocardial ischemia and application thereof
A myocardial ischemia and drug technology, applied in the field of drugs, can solve problems such as no research reports on the prevention and treatment of myocardial infarction with glucosamine.
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- Publication Date
- 2021-10-08
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the pharmaceutical technology, and relates to a medicine for preventing and treating heart failure after myocardial ischemia and an application thereof, in particular to the application of glucosamine in preparing medicines for preventing and treating myocardial infarction. Background technique
[0002] Myocardial infarction (MI) is a cardiovascular disease that seriously endangers human health. With the continuous improvement of people's living standards in our country, the incidence of ischemic myocardial infarction is also increasing. Ischemic myocardial infarction leads to necrosis and scarring of cardiomyocytes, which in turn affects cardiac function. Most of the current drug or device treatments can only relieve the symptoms, but they cannot reverse the damage to the heart tissue. Although heart transplantation can completely improve the state of the heart, it is difficult to be widely used clinically due to factors such...
Examples
Embodiment 1
[0023] Example 1 GlcN effectively improves cardiac function after myocardial infarction
[0024] Cardiac function after myocardial infarction detected by echocardiography
[0025] Mice were anesthetized (the same method as before), placed in the left lateral position after depilation, placed the probe of the cardiac ultrasound diagnostic instrument on the anterior wall of the heart, and took a two-dimensional short-axis view of the left ventricle at the level of the papillary muscle, and recorded M-scan at the same time, for 3 consecutive Cardiac cycle measurements of left ventricular ejection fraction (EF) and fractional shortening (FS).
[0026] Experimental results: Cardiac function was detected 28 days after myocardial infarction, and the GlcN prevention and treatment group significantly improved cardiac function after myocardial infarction ( figure 1 A), ejection fraction ( figure 1 B) and minor axis shortening ( figure 1 C) Significantly improved. * P P < 0.01.
Embodiment 2
[0027] Example 2: GlcN effectively slows down ventricular dilatation after myocardial infarction
[0028] The mice were sacrificed 56 days after the operation, and the body weight (BW), heart weight (HW) and tibia length (TL) of the mice were measured; HW / BW ( figure 2 A) and HW / TL ( figure 2 B). Experimental results: the degree of heart dilation in the GlcN prevention and treatment group was relatively small ( figure 2 ); *P < 0.05.
Embodiment 3
[0029] Example 3: GlcN effectively reduces the size of myocardial infarction
[0030] Masson staining: the mice were sacrificed 56 days after the operation, and the left ventricle tissue was taken for cardiac tissue staining to observe the therapeutic effect. Follow the routine Masson staining procedure, observe and take pictures under an ordinary light microscope. The image analysis software Image J was used to analyze the area of each part, and the myocardial infarction area / heart area was calculated. Experimental results: Holistic view of the heart ( image 3 ), location of myocardial infarction and section ( Figure 4 A), Masson staining was used to observe the myocardial infarction surface 56 days after myocardial infarction in each group ( Figure 4 B), infarct size ( Figure 4 C), it was found that the GlcN prevention and treatment group significantly reduced the size of myocardial infarction; *P < 0.05.
[0031] 【Conclusion】The results of the above experiments c...